Critical Contribution of Pharmacists in Optimising Medication Safety among Children: A Narrative Review

1. Assistant Professor, Department of Pharmacy Practice, Gurugram Global College of Pharmacy, Farrukhnagar, Gurugram, Affiliated to Pt. BD Sharma University of Health Sciences, PGIMS, Rohtak, Haryana, India. 2. Professor and Principal, Department of Pharmacology, School of Pharmaceutical Sciences, COER University, Roorkee, Uttrakhand, India. 3. Professor, Department of Pharmacy Practice, SGT College of Pharmacy, SGT University, Gurugram, Haryana, India.

Abstract

Paediatric patients are particularly vulnerable to medication errors and Adverse Drug Reactions (ADRs), with the incidence of adverse drug events being three times higher in children compared to adults. Given the complexity of paediatric care, it is essential that all healthcare professionals involved in paediatric medication management receive specialised training. Paediatric patients require individualised dosing, careful monitoring and age-appropriate formulations. The administration of the right drug to the right paediatric patient for the right indication, in the right amount, using the right route of administration, at the right time, and for the right duration forms the basis of rational therapeutics. The lack of availability of paediatric-appropriate medications necessitates urgent discussions among the health department, regulatory bodies, medical specialists and the pharmaceutical sector. The present review paper was aimed to identify the challenges associated with the development of paediatric formulations and Drug-related Problems (DRPs) faced by children, emphasising the critical role of pharmacists in addressing these issues, thus enhancing paediatric patient safety. Pharmacists, with their specialised knowledge and skills, are uniquely positioned to optimise medication therapy in paediatric care. They can significantly reduce medication errors by verifying dose calculations, identifying and mitigating potential drug interactions, and counselling caregivers on proper medication administration and storage. Additionally, pharmacists can serve as educators and communicators within the healthcare team, helping to minimise ADRs and improve their management and reporting. The present review study advocates for the increased involvement of pharmacists in paediatric care, recognising their potential to enhance therapeutic outcomes and safeguard paediatric patients from preventable medication-related harm.

Adverse drug reactions, Drug-related problems, Medication error, Paediatric

Ensuring the right medication is administered to the right patient, at the right time, in the right dose, by the right route, for the right disease by the healthcare team forms the basis of medication safety. The vast majority of currently available medications are designed for use in adults, making it particularly challenging to provide pharmacological care to paediatric patients. The percentage of drugs studied for the paediatric age group remains below 50% (1). For this reason, many medications administered to paediatric patients are either not approved for use in this population or are utilised in ways other than those intended by the manufacturer. Together, these factors raise the risk of medication errors, which can diminish their effectiveness. Medication errors have been linked to a lack of knowledge and training among healthcare professionals, varying patient characteristics, environmental factors, prescribing errors and lack of communication (2).

Drug therapy in children is already challenging due to age-related differences in pharmacokinetics and pharmacodynamics. Not all drugs elicit the same response in infants, children, or adolescents, owing to differences in their pharmacokinetic processes, such as absorption and metabolism. It has been reported that 30-40% of paediatric patients experience at least one DRP, which may result in treatment failure, increased follow-up visits, the need for additional treatment, and increased costs (3). Most of these DRPs can be prevented by including clinical pharmacists as medication experts. Paediatric populations are more vulnerable to ADRs than adults. There is a lack of information on clinical trials regarding ADRs in children, leading to a paucity of robust information on the ADR profiles of several drugs (3),(4),(5).

Therefore, a comprehensive, multidisciplinary and integrated approach is essential for ensuring the safe use of medications in children, and achieving improved patient outcomes. Pharmacists have the opportunity to raise the standard of paediatric healthcare at multiple levels. Their expertise in dose calculations based on age and weight, attention to detail, strong communication skills, and deep knowledge of pharmacology, pharmacotherapeutics and pharmaceutics make them invaluable in optimising medication safety for children. They can educate and counsel patients and their caregivers/parents, as well as provide evidence-based information and advice to healthcare workers to ensure the delivery of the correct, safest, and most effective medications to children [6-8]. The present review explores the major challenges in paediatric medication development and safety, and emphasises the critical role of pharmacists in addressing these issues to enhance paediatric patient care.

Challenges Associated with Development of Paediatric Medication

Traditionally, pharmaceutical research has concentrated on developing treatments for adults. Since there exists a non uniformity across various aspects within different age groups in children, the information provided for drug molecules is not readily suitable for direct application in the paediatric population. There is a scarcity of validated biomarkers that are appropriate for use in this population. Additionally, limited data is available to conduct paediatric studies; consequently, the number of drugs prescribed to the paediatric population has not been fully studied, especially in infants and neonates. Historically, clinical trials have predominantly included adults and rarely included children. Because of this, there is a demand for paediatric-labelled formulations and a market for children that is currently being neglected. Moreover, children represent a growing and changing population, even over the course of a single research study. Therefore, studies involving children are more difficult to plan and assess. Ethical concerns arise, in addition to the necessity of obtaining consent from both parents and subjects (9).

Due to the incomplete development of the Blood Brain Barrier (BBB) in newborns, certain lipid-soluble drugs, such as general anaesthetics, sedatives and narcotic analgesics, can have increased permeability. This is why neonates and infants are more sensitive to these drugs. Intravenous administration is preferred for seriously ill newborns. Drugs applied topically are readily absorbed, as the skin is well hydrated and the stratum corneum is thin.

Total body fat in preterm infants is about 1% of total body weight compared with 15% in full-term neonates (10). Weight-related loading doses of aminoglycosides, aminophylline, digoxin and furosemide need to be larger for neonates than for older children. Another factor determining drug distribution is drug binding to plasma proteins (11). Neonates have low protein binding capacity; hence, the fraction of free drug increases in plasma. For some drugs, the volume of distribution increases. For example, digoxin is distributed highly in the myocardium and in skeletal muscle in newborns. Additionally, salicylates are distributed in different body systems, such as the Central Nervous System (CNS), leading to salicylism. Some drugs compete with serum bilirubin for binding to albumin. Drugs given to neonates with jaundice can displace bilirubin from albumin, and this lipid-soluble bilirubin can cross the BBB to cause kernicterus; an example of this is sulfonamides (12).

Due to neonates’ decreased ability to metabolise drugs, many drugs exhibit slow clearance rates and prolonged elimination half-lives. For instance, chloramphenicol-induced fatal gray baby syndrome in newborns occurs because of the decreased metabolism of chloramphenicol by glucuronyl transferase to the inactive glucuronide metabolite. Furthermore, infants have a greater capacity to carry out sulfate conjugation than adults. The increased metabolism by cytochrome P450 and enhanced sulfation explain its decreased hepatotoxic effects when given to children under six years of age. Phase II enzyme reactions mature between 3-6 months (13).

The renal excretory system matures over the first year of age. Drugs eliminated by the kidneys, such as aminoglycosides, penicillins and diuretics, require reduced doses. After six months of age, body weight and surface area-related daily doses are the same for all ages (13).

Technology requirements for drug delivery are also pressing issues when developing paediatric medicines (14). As young patients often face swallowing difficulties, they may become non compliant; therefore, some medications need to be formulated as liquid orals, soluble films, or small-sized soluble tablets to make them more accessible. Some of these dosage forms require specialised methods, and it is possible that these technologies are not always readily available; instead, they may need to be developed locally or purchased from a third party, both of which can be expensive.

Excipients used in developing dosage forms are widely acknowledged as safe, and the vast majority are also non toxic, although not all of them are appropriate for use in paediatric dosages (15). There is a lack of information on the usability and efficacy of excipients for children of varying ages and stages of development. In addition, factors such as age, weight, immature organ systems, the presence or absence of certain enzymes, and their fluctuating quantities all impact excipient metabolism in young patients. Hence, an additional difficulty not faced by adults is the possibility of unfavourable reactions in children caused by the excipients utilised in these medications.

Consideration of additional safety issues, including those related to growth and development, examination of alternative purposes, and the need for multicentric or even worldwide trials to enroll enough patients are just a few of the challenges that must be overcome (16),(17).

Addressing the Challenges in Developing Paediatric Medications

For the very first time in India, guidelines for conducting clinical trials in the paediatric population were laid down and released as the ‘National Ethical Guidelines for Biomedical Research Involving Children’ by the Indian Council of Medical Research (ICMR) (18). These guidelines address the ethical issues of conducting research involving children, describe the assessment of benefits and risks in research, and outline informed consent, assent and general guidelines for research in children in special situations.

Such guidelines for the paediatric population are now also available in other countries, including the Institute of Medicine guidelines in the United States (U.S.), the Medical Research Council guidelines in the United Kingdom (U.K.) and the European Union (EU) guidelines (19).

The formulation for paediatric use should be bioequivalent to a product used for adults to reduce prescribing errors. The formulations for paediatric use must be appropriate in terms of the drug’s dose, convenience and acceptability to children to ensure medication adherence. While formulating drugs for paediatric patients, the differences in physiology compared to adults must be considered to avoid any variations in the drug’s pharmacokinetic profile. Important factors such as the child’s age, ability to swallow and ease of administration should be taken into account when choosing medications for paediatric use. The characteristics of the formulation must be understood to select the right dosage form. Age-appropriate excipients should be chosen for paediatric use to minimise the risk of toxicity due to excipients (20).

The taste of medication is a very important parameter in paediatric use (20). An unacceptable taste of a drug can be masked by mixing it with flavored syrups, such as acetaminophen syrup. The most preferred formulation for paediatric use is an oral liquid, due to its ease of swallowing and the ability to provide doses based on the child’s weight (20). Another property of liquid formulations is that they can be mixed with various flavors during administration, which can improve taste and mask the smell of a drug (21),(22). Oral liquid drops, such as those for the polio virus and rotavirus vaccines, can conveniently deliver small volumes of medicine to very young children. Small-sized dispersible and mouth-dissolving tablets are also accepted by paediatric patients (20).

Various other dosage forms used for paediatric patients include chewable tablets, powders, granules and pellets, due to the greater stability of solid dosage forms compared to liquid forms. Inhaled medicines are often prescribed to newborns and small children with asthma and cystic fibrosis. Airway size, respiratory rate, inspiratory and expiratory flow rates, and breathing patterns, as well as, lung sizes and capabilities, vary significantly throughout the early months and years of life. Dose modification is straightforward for the paediatric use of inhaled drugs since it is based on body weight; adult doses can be extrapolated to find suitable doses for patients aged 3-12 years (23). For inhaled medications, the delivery mechanism impacts dosage, which is crucial for young patients (23). Suppositories and other rectal dosage forms are considered appropriate for paediatric patients, such as diazepam, for those who may have difficulty swallowing pills and capsules (20).

Another suitable dosage form for the paediatric population is transdermal drug delivery systems, due to the avoidance of first-pass metabolism, regulated release and enhanced patient compliance (20). Gummies are also preferred for formulating moisture-sensitive drugs in children (20),(21),(22),(23),(24),(25).

Medication Errors in Paediatric Population

Paediatric patients are unique and should not be considered young adults when prescribing medicines. Mistakes made at any point in the medication use process, whether during prescribing, transcribing, dispensing, administering, or monitoring are considered medication errors (26). The paediatric population is particularly vulnerable to these errors. Medication errors can result in significant harm, including morbidity and mortality, depending on their severity. In addition to affecting the patient, such errors also impact families and healthcare providers by increasing hospital expenditures, prolonging hospital stays, and causing psychological distress. Available literature reports approximately 7.5 million preventable medication errors in paediatric patients in the United States alone each year (27). A study in India reported one medication error for every 9.5 paediatric patients (28). A systematic review conducted in 2019 for paediatric Intensive Care Units (ICUs) reported a median rate of paediatric medication errors as 14.6 per 1,000 medication orders (29). According to the World Health Organisation (WHO), the global cost associated with medication errors has been estimated at 42 billion dollars annually (30). If these mistakes are not avoided, they could lead to undesirable consequences.

Children in the ICU are at increased risk of such errors due to the complexity of their treatment plans. Treatment for many diseases requires intravenous administration, which typically involves diluting or reconstituting the drug. Antibiotics, electrolytes, fluids, analgesics, sedatives and proton pump inhibitors usually carry a higher risk of causing adverse effects in young patients (31). Lack of communication between doctors and patients is also a major contributor to medication errors. Prescribing or administering an inappropriate dosage of drugs is one of the most common types of pharmaceutical errors reported in the literature. According to research, about 5% of all drug prescriptions contain an error, with wrong doses accounting for 28% of those cases (32).

A prospective observational study conducted in 2023 reported that in a paediatric Emergency Department, 218 medication errors were identified in patients under 16 years of age, and these were analysed by clinical pharmacists (33). The most common error was the wrong dose, which accounted for 51.4%, while the wrong or inappropriate drug made up 46.8%. Serious ADRs were noted in 66.2% of cases, while wrong or improper drug errors comprised 29.7%, and drug or dose omission errors accounted for 13.5% (33). Researchers in a Paediatric Emergency Room in the United States discovered that incorrect drug administration accounted for 30% of all medication mistakes (33). In most cases, this was due to confusingly similar packaging or medicine names. Retrospective research conducted in the United Kingdom found that incorrect drug administration accounted for 12% of all prescription mistakes (2). Premature infants and those younger than one year also appear to experience frequent medication errors. Such mistakes can prove to be particularly detrimental for premature infants and those under one year of age (29).

Pharmacist Intervention in Paediatric Medication Errors

Pharmacists are medication experts who bridge the gap between patients and physicians, providing optimal care to patients. A study conducted in a tertiary care hospital in Saudi Arabia reported 1,128 (68.2%) preventable medication errors identified by pharmacists in patients aged 1-6 years (33). The order of medication errors was prescriber-related, followed by patient-related and finally drug-related (34). A retrospective study evaluating electronic medical records in Riyadh showed 2,564 pharmacist interventions related to prescription errors, including dose adjustments (44.0%), restricted medication approvals (21.9%) and therapeutic duplications (11%) (35).

Clinical pharmacists play a significant role in the healthcare team due to their expertise and knowledge about drugs, as well as, their interactions with physicians, nurses and patients. Some intervention studies across the globe involving clinical pharmacists have significantly contributed to a decrease in medication errors and are listed below. Studies have reported that the introduction of computerised physician order entry has led to a decrease in medication errors (36),(37). Clinical pharmacists can play a crucial role in reviewing computerised physician order entries (36),(37). The participation of clinical pharmacists in ward rounds and the monitoring of patients’ drug therapy in the Neonatal Intensive Care Unit (NICU) in Indian hospitals resulted in a 68.97% acceptance rate and changes in drug therapy (38). Common errors included dose and frequency inappropriateness (40.22%), followed by administrative errors (31.05%) and drug interactions (17.24%) (39).

A cross-sectional descriptive study carried out in a Paediatric Inpatient Department in Côte d’Ivoire showed that interventions by clinical pharmacists included 31.8% dose adjustments, 29.3% accuracy of drug administration modalities, and 27.6% proposed therapeutic choices, leading to significant clinical impacts in therapeutic optimisation (39). A study in Pakistan reported a significant reduction in omission errors, which comprised 99.62% of all errors, through the education and training of nurses by clinical pharmacists (40),(41),(42). In Malaysia, significant reduction in medication errors was reported, with the error rate decreasing from 44.3-28.6% by involving pharmacists in creating awareness among general medical ward staff members (43). Interventions by pharmacists can play a significant role in reducing medication errors in the paediatric population (38),(39),(40),(41),(42),(43).

The most common type of medication errors includes administration errors. Examples include incorrect administration, such as injectable amoxicillin/clavulanic acid given at the wrong amount or incorrect rate to children, dosing errors like carbamazepine given as 180 mg instead of 150 mg, and underdosing of digoxin and gentamicin (38),(39),(40),(41),(42),(43). A prospective, single-blinded study conducted in Jordan in 2017 showed that clinical pharmacist interventions in tertiary care hospitals, including patient care education, significantly improved asthma control and quality of life in children and adolescents (44). Similarly, a cross-sectional study conducted from September 2017 to May 2018 in a tertiary care hospital in Iran reported that 54% of clinical pharmacist interventions occurred at the prescribing level, focusing on drug selection and dosing in hospitalised children (45).

Clinical pharmacist interventions played a vital role in identifying and mitigating the burden of medication errors, which included 59.3% prescription errors, 21% administration errors, 10.4% dispensing errors and 8.6% transcription errors, in a Paediatric ICU at a hospital in India (46). Another study carried out in a teaching hospital in Iraq emphasised the role of clinical pharmacists in recognising, reporting and preventing 119 medication errors in infants and toddlers (47). Clinical pharmacist-led interventions among cardiology patients in Palestine reported a 97.6% acceptance rate for interventions by cardiologists. Common DRPs were related to treatment effectiveness (50.8%) and safety (30.4%), with causes including errors in dosing instructions and improper combinations of drugs (48).

Adverse Drug Reactions (ADR) in Paediatric Population

Off-label use of drugs is a common practice in the paediatric population, even in the absence of strong supporting scientific evidence (49). Off-label use refers to the prescribing or administration of drugs beyond the terms of their marketing authorisation regarding therapeutic indication, dose, frequency, age, or route of administration. In contrast, unlicensed use of drugs means modifying the formulation of licensed drugs, manufacturing drugs as extemporaneous preparations, importing or using drugs before a license is granted, or using chemicals as drugs due to a lack of such formulations (49). The benefit-risk assessment for the use of off-label and unlicensed medications varies considerably between young and adult patients (50).

Moreover, children are especially prone to unwanted and harmful effects of drugs due to pathophysiological developmental changes, which result in marked effects on pharmacokinetics and pharmacodynamics. Unexpected adverse effects in children may differ from those seen in adults (51). Chronic therapy with phenobarbital can significantly affect learning and behaviour in children (51), while children are at risk of delayed development and growth suppression with corticosteroid therapy (52). Children under the age of two years are at a higher risk of hepatotoxicity from valproic acid than adults (53). Long-term use of aspirin can lead to Reye’s syndrome in patients with chickenpox (51). The use of phenothiazines can cause extrapyramidal reactions, and tetracyclines can result in discolored teeth in children. Additionally, the low level of P-glycoprotein transporters at birth can explain the increased sensitivity of neonates to opioids compared to older children (53).

ADRs in the paediatric patient population are a significant concern, as drugs that are safe for adult patients cannot be directly extrapolated to children (54). Literature suggests that ADRs are both detectable and preventable. Pharmacists play a pivotal role in the detection, identification, prevention, management, evaluation, documentation and communication of ADRs (55).

Pharmacists can provide important care for inpatients by reviewing medication charts during ward rounds and managing medications in prescriptions. Several studies worldwide highlight that the off-label use of drugs, polypharmacy, and the irrational use of antibiotics in paediatric patients are responsible for the majority of ADRs (56). An analysis of medical records for 301 paediatric patients in a university hospital in the Netherlands identified 132 cases of ADRs as a result of unlicensed and off-label drug use (57). The study also emphasised that underreporting of ADRs is a significant issue among paediatric patients, finding that only an average of 513 ADR reports were made annually in the Netherlands (57).

Allen LV Jr, reported a retrospective study conducted at a teaching hospital in Odisha, India, from 2015 to 2020, where 105 ADRs were detected. Of these, 41% affected children in the age group of 0-5 years, and 21% of the cases were classified as serious (5). The most common ADRs were cutaneous reactions (86.5%), primarily attributed to antibiotics (66%) (58).

A study by Leitzen S et al., analysed 20,854 spontaneous ADR reports from 2000 to 2019. The majority (86.5%) of the reports originated from healthcare professionals, while 12.2% came from non healthcare professionals. Additionally, 74.4% of the reports were classified as serious. Interestingly, only 3.5% of these reports involved off-label use (58). Rani N et al., reported that out of a total of 14 ADRs detected in paediatric patients at a tertiary care hospital in Haryana, India, most of the ADRs were due to antibiotics affecting children between the ages of 3-5 years (59).

Role of Pharmacist in Adverse Drug Reaction (ADR)

Many studies have suggested that ADRs are detectable and preventable [55-60]. Pharmacists play a crucial role in the detection, identification, prevention, management, evaluation, documentation and communication of ADRs. Their interventions include reporting and managing ADRs and events, improving health-related quality of life, addressing economic concerns, ensuring medication appropriateness and enhancing patient satisfaction and adherence (60).

Pharmacists can be pivotal in the care of inpatients by reviewing medication charts during ward rounds and managing the medications prescribed (54). Development of ADR monitoring systems in hospitals can also be facilitated by pharmacists. Reporting ADRs is a critical aspect of monitoring and evaluating activities performed in hospital settings (60).

The role of pharmacists in paediatric patient care and safety has increased significantly. Clinical pharmacists have a greater role in NICUs and in managing patients diagnosed with chronic disorders, particularly regarding dose alterations and pharmacokinetic recommendations (61). The incidence rate of 5.5 interventions per patient in paediatric ICUs has been shown to significantly impact patient health outcomes (61). Pharmacists play a leading role in ensuring the right treatment, as well as, the safety and effectiveness of drugs (62).

Pharmacists also have an educational role, as they possess the necessary skills to address safety concerns related to patients and medications. DRPs encompass medication errors, ADRs, and adverse drug events. A prospective study conducted at a children’s hospital in Vietnam demonstrated that pharmacist-led interventions significantly reduced DRPs, including inappropriate timing of administration and incorrect dosages, from 66.1-45.5% (p-value <0.001) (50).

Another prospective study conducted in three Paediatric Wards in Saudi Arabia involved clinical pharmacists, Paediatricians and interns analysing DRPs. A total of 596 DRPs were reported, with the highest incidence at 15.2% due to inappropriate drug choice, while 5.2% were classified as major DRPs. Additionally, 33.2% of DRPs were related to metabolism and the digestive system (63). The predominant DRP was associated with dosing problems.

A study evaluating the prevalence and various DRPs led by clinical pharmacists found that out of 174 patients, one DRP was observed in 16% of the patients (64). In total, 527 DRPs were identified, with drug-drug interactions found in 64.70%, therapeutic monitoring DRPs at 39%, and dosing issues at 1% (64).

The role of pharmacists has evolved and expanded in providing paediatric patient care, as well as, educating parents and healthcare professionals for effective reporting of ADRs. Some of the recent interventions by pharmacists that have led to a decrease in DRPs are listed in (Table/Fig 1) (65),(66),(67),(68),(69),(70),(71),(72).

Conclusion

The heterogeneity of paediatric patients makes them more vulnerable to drug-related problems compared to adults, complicating their care. The development of medication for children is also a challenging process. Pharmacists are medication experts equipped with the necessary knowledge and skills to improve patient health outcomes. They can educate and counsel patients, caregivers/parents and healthcare workers, to provide optimised and safe medication use in paediatric patients. The role of pharmacists is crucial in reducing and managing medication errors and ADRs, as well as, in ensuring the delivery of the right medication in the right dose to children of all age groups.

Acknowledgement

The authors would like to acknowledge and express gratitude to parent Institution for providing the necessary facilities for writing the present review.

DOI and Others

DOI: 10.7860/JCDR/2025/75234.20814

Date of Submission: Sep 01, 2024
Date of Peer Review: Nov 21, 2024
Date of Acceptance: Jan 01, 2025
Date of Publishing: Apr 01, 2025

AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was informed consent obtained from the subjects involved in the study? No
• For any images presented appropriate consent has been obtained from the subjects. NA

PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Sep 09, 2024
• Manual Googling: Dec 14, 2024
• iThenticate Software: Dec 30, 2024 (11%)

ETYMOLOGY: Author Origin

EMENDATIONS: 5